HT
KPTI icon

Headlands Technologies’s Karyopharm Therapeutics KPTI Stock Holding History

Headlands Technologies’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$118K Buy
+12,113
New +$105K 0.01% 654
2024
Q2 		– Sell
-83
Closed -$1.88K – 1392
2024
Q1 		$1.88K Buy
+83
New +$1.46K ﹤0.01% 1168
2023
Q4 		– Sell
-921
Closed -$18.5K – 1134
2023
Q3 		$18.5K Buy
+921
New +$20.7K 0.01% 600

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Headlands Technologies's KPTI Position: Q2 2026 in Review

Headlands Technologies opened a new position in Karyopharm Therapeutics (KPTI) in Q2 2026: 12,113 shares worth $118K. The stake represents 0.01% of the portfolio and ranks #654 among its holdings. This is a return to the name: Headlands Technologies previously reported a position in KPTI as recently as Q1 2024.

Headlands Technologies first reported a position in KPTI in Q3 2023 and has held it in 3 quarters since. 96 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • Headlands Technologies held 12,113 shares of Karyopharm Therapeutics worth $118K as of Q2 2026.
  • Karyopharm Therapeutics was a new Headlands Technologies position in Q2 2026.
  • Karyopharm Therapeutics made up 0.01% of Headlands Technologies's portfolio in Q2 2026, its #654 holding.
  • Headlands Technologies first reported a position in Karyopharm Therapeutics in Q3 2023 and has held it in 3 quarters since.
  • 96 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.